Form 4: Sutro Biopharma Executive Reports Stock Transactions

Venkatesh Srinivasan, Chief Technical Operations Officer of Sutro Biopharma, reports the vesting and withholding of shares to cover tax obligations.

Summary

• Venkatesh Srinivasan, Chief Technical Operations Officer of Sutro Biopharma, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On March 1, 2025, Mr. Srinivasan vested 5,000 and 6,375 shares of common stock related to Restricted Stock Units (RSUs).
• The company withheld 4,672 shares at a price of $1.59 to cover income tax obligations related to the RSU vesting.
• Following these transactions, Mr. Srinivasan directly owns 38,433 shares of Sutro Biopharma common stock and 10,000 and 19,125 Restricted Stock Units.
• The RSUs vest annually, with the first tranche of the 5,000 RSU grant vesting on March 1, 2024, and the first tranche of the 6,375 RSU grant vesting on March 1, 2025.

Sentiment

Score: 7

Explanation: The document reflects routine insider transactions related to equity compensation, which is generally a neutral to slightly positive indicator as it aligns management's interests with shareholders.

Positives

• The vesting of RSUs indicates that Mr. Srinivasan is meeting the service requirements of his equity grants.

Future Outlook

The reporting person will continue to vest in RSUs subject to continued service with the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Comparison to Industry Standards

• Equity compensation is a common practice in the biotechnology industry to attract and retain talent.
• RSUs are a standard form of equity compensation, offering employees a stake in the company's success.
• The vesting schedules and terms of these RSUs are likely comparable to those offered by other biotechnology companies of similar size and stage.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they primarily reflect internal compensation arrangements.
• Shareholders may view the vesting of RSUs as a sign of continued commitment from the executive.

Key Dates